Omeros Reveals ASH Presentations
Omeros Corporation announced two upcoming presentations on their investigational MASP-3 inhibitor, zaltenibart (OMS906), at the 66th Annual Meeting of...
New Biovanta Study Shows Best Efficacy for Common Cold
The common cold carries a substantial economic burden, causing approximately $40 billion in annual productivity losses. A recent study...
Rallybio Confirmatory Study Launch in Q2 2025
Rallybio Corporation announced new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous C5 inhibitor for...
Daiichi Sankyo Oncology Progress at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO...
Zorevunersen Data for Dravet Syndrome at AES 2024
Stoke Therapeutics, a biotechnology company focused on RNA medicine, will present data at the 2024 American Epilepsy Society (AES)...
Sudo Biosciences Doses First Participants in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor Sudo-550
Sudo Biosciences, a company focused on developing precision TYK2 inhibitors, has initiated a Phase 1 clinical trial for SUDO-550....
Transforming Clinical Trials with Generative AI: Insights from Medable
In this interview, we speak with Tim Smith, co-founder and CTO at Medable, to discuss AI’s role in addressing...
Addressing Clinical Trial Diversity: Challenges, Opportunities, and Critical Capabilities
The 2024 SCOPE Europe conference featured a presentation on clinical trial diversity, highlighting the critical need for diversity and...
Stem Cell Market Growth, Challenges, and Opportunities to 2028
The global induced pluripotent stem cells (iPSCs) market is poised for significant growth, projected to increase from $3.4 billion...
Rlyb212 Dosing in Pregnant Women: Target-Mediated Drug Disposition
Rallybio Corporation published a manuscript detailing a novel model for determining drug dosage in pregnant women, specifically for their...